DGAP-News: Passing of Genmab A/S' Annual General Meeting

(firmenpresse) - Genmab A/S

06.04.2011 17:03
---------------------------------------------------------------------------

-- At Genmab A/S' Annual General Meeting held today on April 6, 2011 the
Annual Report for 2010 was approved
-- Discharge was given to the Board of Directors and the Executive Management
and the year's loss was carried forward
-- PricewaterhouseCoopers was re-elected as auditor of the Company
-- The proposal from the Board of Directors on general guidelines for
incentive-based remuneration, the proposal on the Board of Directors'
remuneration for 2011 and the proposals to amend Article 4A and Article 12
of the Articles of Association were adopted
-- A new member was elected to the Board of Directors and two members of the
Board of Directors were re-elected

Copenhagen, Denmark; April 6, 2011 - Genmab A/S (OMX: GEN) held its Annual
General Meeting, today April 6, 2011 at 2:00 PM at Radisson Blu Scandinavia
Hotel, Copenhagen, Amager Boulevard 70, DK-2300 Copenhagen S, Denmark.

At the meeting Chairman of the Board of Directors Dr. Michael B. Widmer gave -
on behalf of the Board of Directors - a report on the Company's activities
during the past year. Chief Executive Officer Jan van de Winkel presented plans
for the year ahead, and Chief Financial Officer David Eatwell presented the
Annual Report for 2010 endorsed by the auditors. The report was approved and
discharge was given to the Board of Directors and the Executive Management.

It was decided that the year's loss of DKK 279 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.

PricewaterhouseCoopers Statsautoriseret Revisionsaktieselskab A/S was
re-elected as the Company's auditor.

The General Meeting adopted the proposals from the Board of Directors, as
follows:



-- The proposal to adopt revised general guidelines for incentive-based
remuneration for the Board of Directors and the Executive Management.
-- The proposal to adopt the Board of Directors' remuneration for 2011.
-- The proposal to amend Article 4A of the Articles of Association so that the
existing authorization to issue nominally DKK 15,000,000 shares is
prolonged to five years from the General Meeting.
-- The proposal to amend Article 12 of the Articles of Association so that the
General Meeting elected members of the Board of Directors are elected for a
period which expires at the Annual General Meeting in the Company in the
second year after the year of their election. Furthermore, the reference to
Lisa N. Drakeman is deleted.

Toon Wilderbeek were elected to the Board of Directors for a two year period.
Michael B. Widmer and Karsten Havkrog Pedersen were both re-elected to the
Board of Directors for a two year period.

About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.

Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr?;
HuMax-IL8?; HuMax-TAC?; HuMax-CD38?; HuMax-TF?; HuMax-Her2?; HuMax-Wnt?;
HuMax-cMet?, DuoBody? and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.

Stock Exchange Release no. 13
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
News Source: NASDAQ OMX



06.04.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Genmab A/S


Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
Datum: 06.04.2011 - 17:03 Uhr
Sprache: Deutsch
News-ID 382374
Anzahl Zeichen: 6836

Kontakt-Informationen:

Kategorie:

Wirtschaft (allg.)

Diese Pressemitteilung wurde bisher 336 mal aufgerufen.

DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 ...
Genmab A/S 15.05.2012 17:01 --------------------------------------------------------------------------- May 15, 2012; Copenhagen, Denmark; Interim Report for the First Quarter 2012 -- Arzerra(r) net sales increased 32% over Q1 2011 -- New Drug Application for ofatumumab submitted in Japan

DGAP-News: Passing of Genmab A/S' Annual General Meeting ...
Genmab A/S 25.04.2012 15:57 --------------------------------------------------------------------------- - At Genmab A/S' Annual General Meeting held today on April 25, 2012 the Annual Report for 2011 was approved - Discharge was given to the Board of Directors and the Executive Management a

DGAP-News: Genmab Revised Financial Calendar for 2012 ...
Genmab A/S 18.04.2012 10:54 --------------------------------------------------------------------------- Copenhagen, Denmark; April 18, 2012 - Genmab A/S (OMX: GEN) announces a revised financial calendar for 2012. The interim financial report for the first quarter of 2012 will now take place on Tu

Weitere Mitteilungen von Genmab A/S

Deutschland und Abu Dhabi: Zusammenarbeit bei der Industriezone Kizad ...
Hannover, 5. April 2011. Das Bundesministerium für Verkehr, Bau und Stadtentwicklung und das Ministerium für wirtschaftliche Entwicklung in Abu Dhabi haben heute während der Hannover Messe Industrie in einer gemeinsamen Absichtserklärung engere Zusammenarbeit bei der Entwicklung, Förderung und

Focus Minerals: Kapitalbeschaffung zur Erhöhung der Goldproduktion auf 130.000 Unzen & Beschleunigung der Exploration ...
Focus Minerals: Kapitalbeschaffung zur Erhöhung der Goldproduktion auf 130.000 Unzen & Beschleunigung der Exploration Platzierung in Höhe von 32,3 Millionen $ und Aktienbezugsplan (SSP) in Höhe von 7 Millionen $ • Stark befürwortete Platzierung

"RTL - Wir helfen Kindern": Lenovo spendet 37 Computer für die RTL-Kinderhäuser ...
Gezielte Förderung für Kinder in ganz Deutschland: Der weltweit viertgrößte Computerhersteller Lenovo stellt 37 neue Ideacentre B 520 Computer inklusive Microsoft-Office Paket in den RTL-Kinderhäusern in Deutschland auf. So können die Kinder und Jungendlichen Medienkompetenz entwickeln. Auße

Neues Kältemittel von Honeywell mit geringem Treibhauspotenzial wird von US-Umweltschutzagentur für den Gebrauch in PKW genehmigt ...
2011 - Honeywell (NYSE: HON) hat heute bekannt gegeben, dass sein neues Kältemittel mit geringem Treibhauspotenzial (GWP) für den Gebrauch in Automobil-Klimaanlagen die endgültige Genehmigung durch die US-Umweltschutzagentur (U.S. Environmental Protection Agency) erhalten hat. Durch die G